Alejandro Gonzalez Campos, MD
Endocrinology, Diabetes & Metabolism · Edinburg, TXNPI 1508130543
Payments from drug & device makers
Across 670 payments — averaging $1035.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$497K
- Lilly USA, LLC$178K
- Eli Lilly Export S.A. Puerto Rico Branch$12K
- Dexcom, Inc.$2K
- Novo Nordisk$1K
- Ascensia Diabetes Care US Inc.$626
- plus $4K from 31 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 4 | $496,849 |
| Lilly USA, LLC | 362 | $177,950 |
| Eli Lilly Export S.A. Puerto Rico Branch | 1 | $11,896 |
| Dexcom, Inc. | 42 | $1,536 |
| Novo Nordisk | 77 | $1,290 |
| Ascensia Diabetes Care US Inc. | 17 | $626 |
| Corcept Therapeutics | 21 | $500 |
| AstraZeneca(2 entities) | 12 | $467 |
| Insulet Corporation | 8 | $369 |
| Amgen(2 entities) | 29 | $349 |
| Abbott | 14 | $308 |
| Mannkind Corporation | 12 | $299 |
| Janssen Products, LP | 2 | $231 |
| Radius Health, Inc. | 19 | $207 |
| Novartis | 7 | $121 |
| Merck | 1 | $114 |
| Boehringer Ingelheim | 5 | $113 |
| Cequr Corporation | 3 | $99 |
| Philips North America LLC | 1 | $91 |
| Bayer | 4 | $66 |
| Recordati_rare_diseases_inc. | 3 | $64 |
| Amryt Pharma Holdings Ltd | 3 | $61 |
| Sanofi-aventis U.S. LLC | 3 | $52 |
| Amarin Pharma, Inc. | 3 | $51 |
| Madrigal Pharmaceuticals | 2 | $50 |
| Tandem Diabetes Care, Inc. | 3 | $46 |
| Senseonics, Incorporated | 1 | $44 |
| Neurocrine Biosciences, Inc. | 1 | $29 |
| Arbor Pharmaceuticals, Inc. | 1 | $27 |
| Kowa Pharmaceuticals America, Inc. | 2 | $26 |
| Rhythm Pharmaceuticals, Inc. | 1 | $24 |
| Echosens North America, Inc. | 1 | $23 |
| Medtronic | 1 | $23 |
| Xeris Pharmaceuticals, Inc. | 1 | $18 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Tolmar, Inc. | 1 | $14 |
| Johnson & Johnson | 1 | $5 |
How this compares
$694,056 in reported general payments places this provider in the 90th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
See all endocrinology, diabetes & metabolism providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other endocrinology, diabetes & metabolism in Edinburg
- Eduardo LunaEdinburg$7.6M
- Julio RosenstockDallas$24.9M
- Michelle WelchShavano Park$17.3M
- Maria CabanillasHouston$16.4M
- Sumana GangiMesquite$13.2M
- Damaris VegaHouston$12.3M
- Mark KipnesSan Antonio$10.3M
- Amer Al KaradshehHouston$8.8M
- Ildiko LingvayDallas$8.2M
- Thomas BlevinsAustin$7.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.